Growth Hormone Deficiency in Children Clinical Trial
Official title:
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06109935 -
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
|
||
| Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT03672617 -
Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy
|
||
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Completed |
NCT01502124 -
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT01604161 -
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
|
N/A | |
| Active, not recruiting |
NCT03811535 -
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
|
Phase 3 | |
| Recruiting |
NCT02616562 -
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
|
Phase 2 | |
| Completed |
NCT00567385 -
Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 4 | |
| Enrolling by invitation |
NCT03972345 -
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
|
||
| Completed |
NCT03186495 -
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
|
Phase 1 | |
| Completed |
NCT04970654 -
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
|
Phase 3 | |
| Completed |
NCT01500486 -
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
|
N/A | |
| Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
| Completed |
NCT01514500 -
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT01068639 -
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
|
N/A | |
| Completed |
NCT01973244 -
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
|
Phase 1 | |
| Completed |
NCT00936403 -
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
|
Phase 2 | |
| Completed |
NCT00262249 -
Effect of Growth Hormone in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Completed |
NCT03212131 -
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
|
Phase 1 |